A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan-hziy (SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNBC). The primary objectives of this study are to assess the safety and tolerability of SG given at alternate dose and schedule, to assess the effect on objective response rate (ORR) and progression-free survival (PFS).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej, możliwość zrozumienia i podpisania zgody na uczestnictwo w badaniu
- •Potwierdzony nowotwór piersi potrójnie ujemny (TNBC)
- •Zaawansowany nowotwór, który nie reaguje na standardowe leczenie chemioterapią lub inną terapią
- •Dla fazy 2: brak wcześniejszego leczenia przeciwnowotworowego na zaawansowaną chorobę
- •Dla fazy 2: nowotwór musi mieć ujemny wynik testu PD-L1 (CPS < 10) lub pacjent otrzymał leczenie immunoterapią w przeszłości
- •Obecność wymiernego guza widocznego w badaniach obrazowych (CT lub MRI)
- •Dobry ogólny stan zdrowia (skala ECOG 0 lub 1)
- •Prawidłowe wyniki morfologii krwi, funkcji wątroby i nerek
✗ Disqualifies
- •Poprzednie leczenie inhibitorami topoisomerazy 1 lub lekami połączonymi z przeciwciałami zawierającymi inhibitory topoisomerazy
- •Poprzednie leczenie lekami skierowanymi na antygen Trop-2
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- January 30, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (16)
Los Angeles Cancer Network (LACN) - Good Sam
Los Angeles, United States
Winship Cancer Institute - Emory University
Atlanta, United States
The University of Kansas Hospital
Westwood, United States
Siteman Cancer Center
St Louis, United States
West Cancer Centre
Germantown, United States
SCRI Oncology Partners
Nashville, United States
Tennessee Oncology, PLLC
Nashville, United States
Texas Oncology - DFW
Dallas, United States
Virginia Oncology Associates
Norfolk, United States
St. Vincent's Hospital - Kinghorn Cancer Center
Darlinghurst, Australia
Sunshine Coast University Private Hospital
Birtinya, Australia
John Flynn Private Hospital
Tugun, Australia
Seoul National University Hospital
Seoul, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Trial contact
Gilead Clinical Study Information Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.